Friday, September 30, 2022
HomeBiochemistryCelastrol recruits UBE3A to acknowledge and degrade the DNA binding area of...

Celastrol recruits UBE3A to acknowledge and degrade the DNA binding area of steroid receptors

Facebook
Twitter
Pinterest
WhatsApp

  • Groner AC, Brown M. Position of steroid receptor and coregulator mutations in hormone-dependent cancers. J Clin Investig. 2017;127:1126–35.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Tata JR. Signalling via nuclear receptors. Nat Rev Mol Cell Biol. 2002;3:702–10.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Chen Y, Sawyers CL, Scher HI. Focusing on the androgen receptor pathway in prostate most cancers. Curr Opin Pharmacol. 2008;8:440–8.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Furr BJ. The event of Casodex (bicalutamide): preclinical research. Eur Urol. 1996;29:83–95. Suppl 2

    PubMed 
    Article 

    Google Scholar 

  • Scher HI, Fizazi Okay, Saad F, Taplin ME, Sternberg CN, Miller Okay, et al. Elevated survival with enzalutamide in prostate most cancers after chemotherapy. N. Engl J Med. 2012;367:1187–97.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate most cancers earlier than chemotherapy. N. Engl J Med. 2014;371:424–33.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar 

  • Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Improvement of a second-generation antiandrogen for remedy of superior prostate most cancers. Science 2009;324:787–90.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate most cancers. N. Engl J Med. 2014;371:1028–38.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar 

  • Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively lively androgen receptor that mediates prostate most cancers remedy resistance. Most cancers Res. 2008;68:5469–77.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309–22.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate most cancers. Eur Urol. 2015;67:53–60.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Li J, Berk M, Alyamani M, Sabharwal N, Goins C, Alvarado J, et al. Hexose-6-phosphate dehydrogenase blockade reverses prostate most cancers drug resistance in xenograft fashions by glucocorticoid inactivation. Sci Translational Med. 2021;13:eabe8226.

  • Hou Z, Huang S, Li Z. Androgens in prostate most cancers: A story that by no means ends. Most cancers Lett. 2021;516:1–12.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Schneekloth AR, Pucheault M, Tae HS, Crews CM. Focused intracellular protein degradation induced by a small molecule: En path to chemical proteomics. Bioorg Med Chem Lett. 2008;18:5904–8.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Toure M, Crews CM. Small-Molecule PROTACS: New Approaches to Protein Degradation. Angew Chem. 2016;55:1966–73.

    CAS 
    Article 

    Google Scholar 

  • Takwale AD, Jo SH, Jeon YU, Kim HS, Shin CH, Lee HK, et al. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras. Eur J Med Chem. 2020;208:112769.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Zhao L, Han X, Lu J, McEachern D, Wang S. A extremely potent PROTAC androgen receptor (AR) degrader ARD-61 successfully inhibits AR-positive breast most cancers cell progress in vitro and tumor progress in vivo. Neoplasia 2020;22:522–32.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, et al. Discovery of ARD-69 as a Extremely Potent Proteolysis Focusing on Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Therapy of Prostate Most cancers. J Med Chem. 2019;62:941–64.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Alyamani M, Li Z, Berk M, Li J, Tang J, Upadhyay S, et al. Steroidogenic Metabolism of Galeterone Reveals a Variety of Biochemical Actions. Cell Chem Biol. 2017;24:825–32. e6

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Ponnusamy S, He Y, Hwang DJ, Thiyagarajan T, Houtman R, Bocharova V, et al. Orally Bioavailable Androgen Receptor Degrader, Potential Subsequent-Technology Therapeutic for Enzalutamide-Resistant Prostate Most cancers. Clin Most cancers Res: Off J Am Assoc Most cancers Res. 2019;25:6764–80.

    CAS 
    Article 

    Google Scholar 

  • Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype by way of degradation of androgen receptor. Nat Med. 2007;13:348–53.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Most cancers cell. 2006;10:321–30.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese language “Thunder of God Vine,” is a potent proteasome inhibitor and suppresses human prostate most cancers progress in nude mice. Most cancers Res. 2006;66:4758–65.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Chadli A, Felts SJ, Wang Q, Sullivan WP, Botuyan MV, Fauq A, et al. Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23. J Biol Chem 2010;285:4224–31.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP advanced capabilities as a ubiquitin-protein ligase within the ubiquitination of p53. Cell 1993;75:495–505.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interplay of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993;13:775–84.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fang M, Li Y, Ren J, Hu R, Gao X, Chen L. Epilepsy-Related UBE3A Deficiency Downregulates Retinoic Acid Signalling Pathway. Entrance Genet. 2021;12:681295.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ, et al. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol. 1999;19:1182–9.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Khan OY, Fu G, Ismail A, Srinivasan S, Cao X, Tu Y, et al. Multifunction steroid receptor coactivator, E6-associated protein, is concerned in improvement of the prostate gland. Mol Endocrinol. 2006;20:544–59.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Birch SE, Kench JG, Takano E, Chan P, Chan AL, Chiam Okay, et al. Expression of E6AP and PML predicts for prostate most cancers development and cancer-specific loss of life. Ann Oncol: Off J Eur Soc Med Oncol. 2014;25:2392–7.

    CAS 
    Article 

    Google Scholar 

  • Smith CL, DeVera DG, Lamb DJ, Nawaz Z, Jiang YH, Beaudet AL, et al. Genetic ablation of the steroid receptor coactivator-ubiquitin ligase, E6-AP, leads to tissue-selective steroid hormone resistance and defects in replica. Mol Cell Biol. 2002;22:525–35.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Jones JO, An WF, Diamond MI. AR inhibitors recognized by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem Biol. 2009;4:199–208.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Li H, Ban F, Dalal Okay, Leblanc E, Frewin Okay, Ma D, et al. Discovery of small-molecule inhibitors selectively concentrating on the DNA-binding area of the human androgen receptor. J Med Chem. 2014;57:6458–67.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Zhou Y, Li W, Wang M, Zhang X, Zhang H, Tong X, et al. Aggressive profiling of celastrol targets in human cervical most cancers HeLa cells by way of quantitative chemical proteomics. Mol Biosyst. 2016;13:83–91.

    PubMed 
    Article 

    Google Scholar 

  • Salminen A, Lehtonen M, Paimela T, Kaarniranta Okay. Celastrol: Molecular targets of Thunder God Vine. Biochemical Biophysical Res Commun. 2010;394:439–42.

    CAS 
    Article 

    Google Scholar 

  • Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee Okay, et al. Inhibition of NF-kappa B activation via concentrating on I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochemical Pharmacol. 2006;72:1311–21.

    CAS 
    Article 

    Google Scholar 

  • Website positioning HR, Website positioning WD, Pyun BJ, Lee BW, Jin YB, Park KH, et al. Radiosensitization by celastrol is mediated by modification of antioxidant thiol molecules. Chem-Biol Work together. 2011;193:34–42.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Hou Z, Huang S, Mei Z, Chen L, Guo J, Gao Y, et al. Inhibiting 3betaHSD1 to remove the oncogenic results of progesterone in prostate most cancers. Cell Rep Med. 2022;3:100561.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Mei Z, Yang T, Liu Y, Gao Y, Hou Z, Zhuang Q, et al. Administration of prostate most cancers by concentrating on 3betaHSD1 after enzalutamide and abiraterone remedy. Cell Rep Med. 2022;3:100608.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, et al. Androgen receptor degraders overcome widespread resistance mechanisms developed throughout prostate most cancers remedy. Neoplasia 2020;22:111–9.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Proof-of-Idea with PROTACs in Prostate Most cancers. Most cancers Discov. 2020;10:1084. https://doi.org/10.1158/2159-8290.CD-NB2020-054.

  • Lim HY, Ong PS, Wang L, Goel A, Ding L, Li-Ann Wong A, et al. Celastrol in most cancers remedy: Latest developments, challenges and prospects. Most cancers Lett. 2021;521:252–67.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Shi J, Li J, Xu Z, Chen L, Luo R, Zhang C, et al. Celastrol: A Evaluate of Helpful Methods Overcoming its Limitation in Anticancer Utility. Entrance Pharmacol. 2020;11:558741.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Ramamoorthy S, Nawaz Z. E6-associated protein (E6-AP) is a twin perform coactivator of steroid hormone receptors. Nucl Receptor Sign. 2008;6:e006.

    Google Scholar 

  • Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations trigger Angelman syndrome. Nat Genet. 1997;15:70–3.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet. 1997;15:74–7.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Gao X, Mohsin SK, Gatalica Z, Fu G, Sharma P, Nawaz Z. Decreased expression of e6-associated protein in breast and prostate carcinomas. Endocrinology 2005;146:1707–12.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, et al. Mutation of the Angelman ubiquitin ligase in mice causes elevated cytoplasmic p53 and deficits of contextual studying and long-term potentiation. Neuron 1998;21:799–811.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Park JH, Partitions JE, Galvez JJ, Kim M, Abate-Shen C, Shen MM, et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol. 2002;161:727–35.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural foundation of androgen receptor binding to selective androgen response components. Proc Natl Acad Sci. 2004;101:4758–63.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • Xu X, Li C, Gao X, Xia Okay, Guo H, Li Y, et al. Extreme UBE3A dosage impairs retinoic acid signaling and synaptic plasticity in autism spectrum issues. Cell Res. 2018;28:48–68.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • Facebook
    Twitter
    Pinterest
    WhatsApp
    RELATED ARTICLES

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Most Popular

    Recent Comments